The Ebola Treatment You Haven't Heard Of

FORBES       by David Kroll                                                                                              Dec. 19, 2014

Pharmaceuticals and biotechnology-derived products have attracted the greatest public and professional interest in treating victims of Ebola virus disease. But a privately-held, small company with a treatment for shock and multi-organ failure may be the dark horse victor in the race to stop the West African outbreak. LB1148 from San Diego-based Leading BioSciences is starting Phase 2 clinical trials that build on 12 years of NIH-funded research to address an underappreciated, common denominator in shock and organ failure, including shock caused by Ebola infection.

Read complete story.

http://www.forbes.com/sites/davidkroll/2014/12/19/the-ebola-treatment-you-havent-heard-of/